AevisBio, Inc
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
AevisBio, Inc - overview
Established
2018
Location
Daejeon, -, South Korea
Primary Industry
Biotechnology
About
Based in Daejeon, South Korea, and founded in 2018, AevisBio provides a scientific solution for drug development targeting incurable diseases such as inflammatory diseases, neurological disorders, and drug-resistant cancers. The company is building a portfolio of proteolytic drugs based on a novel immunomodulatory amide or IMiD low-molecular compound. Based on IMiD materials, AevisBio is conducting preclinical development targeting degenerative brain diseases such as traumatic brain injury or TBI and licensed the exclusive right to IMiD pomalidomide derivative-related pharmaceutical technology for use as a TPD precursor from the US National Institutes of Health in January 2021. The company develops and manufactures PROTAC, a bivalent proteolytic anticancer drug treatment of intractable diseases based on an immunomodulatory molecule (IMiD) compound.
AevisBio plans to expand its indications to inflammatory diseases based on the inflammation-regulating action of IMiD.
Current Investors
KB Investment, Timefolio Asset Management, We Venture Partners
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment, Specialty Pharmaceuticals
Website
www.aevisbio.com
Verticals
Manufacturing
Company Stage
Series A
Total Amount Raised
Subscriber access only
AevisBio, Inc - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.